New insider activity at Roivant Sciences ( (ROIV) ) has taken place on February 11, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Roivant Sciences has seen a notable insider transaction as President & CIO Mayukh Sukhatme sold 339,441 shares of the company’s stock, with the total value of the sale amounting to $8,985,003. This sizable move may draw investor attention as market participants monitor insider activity for potential signals about executive sentiment toward the company’s outlook.
Recent Updates on ROIV stock
Roivant Sciences’ shares have been buoyed as multiple brokers raised price targets after the company reported strong Phase 2 data for brepocitinib in cutaneous sarcoidosis and detailed the results on its upbeat Q3 earnings call. Analysts cited the encouraging efficacy and clean safety profile, the decision to model new revenue from this indication, and the perception of brepocitinib as a multi‑indication orphan franchise with numerous upcoming pivotal readouts and a large cash buffer that can fund its ambitious pipeline, though they continue to flag trial, regulatory, and commercialization risks.
Spark’s Take on ROIV Stock
According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral.
The score is driven most by mixed financial performance (strong, low-debt balance sheet but ongoing losses and cash burn). Offsetting this, the earnings call was notably positive on clinical progress and upcoming catalysts with substantial cash runway, and technicals show an established uptrend, though near-term momentum looks stretched. Valuation is constrained by lack of profitability (negative P/E).
To see Spark’s full report on ROIV stock, click here.
More about Roivant Sciences
YTD Price Performance: 27.51%
Average Trading Volume: 7,228,776
Technical Sentiment Signal: Buy
Current Market Cap: $19.8B